Tim Aitman (Affiliate)

Genome Medicine

Research in a Nutshell

The Genome Medicine Group combines the use of classical genetics with cutting-edge genome technologies such as whole genome sequencing and epigenomics to unravel the genetics of common complex and rare human disorders. The group has investigated the pathogenesis and developed diagnostic next generation sequencing assays for varied conditions including familial hypercholesterolaemia, Ehlers Danlos Syndrome (EDS), immunologically mediated glomerulonephritis, and motor neurone disease.

In a new collaboration with the Edinburgh Cancer Research Centre, the Genome Medicine Group is developing new methods for analysis of cell-free DNA, for diagnosis and stratification of cancer. Cell-free DNA in the blood of cancer patients contains the same variants as those in the tumour cells, allowing a real-time, non-invasive assessment of the progression of the disease and an indication of response to therapy. Working with oncologists and surgeons in the cancer centre, the group is developing wet lab and informatic approaches to diagnosis of early and late stage disease. Using High Throughput Sequencing and Digital Droplet PCR, somatic mutations specific to breast, ovarian and colorectal cancer are being analysed in cell-free DNA samples. In addition, methods to explore epigenetic changes are being developed that are compatible with low input DNA requirements. Integrated analyses will aim to provide enhanced diagnostic molecular markers in cancer.

This program, alongside advances of others also working in this field, stands to make major advances in cancer management, including monitoring for occurrence of early disease and relapse. 

Research Programme

Contact

tim.aitman@ed.ac.uk

Cancer Research Collaborations

• Olga Oikonomidou
• David Cameron
• Malcolm Dunlop
• Charlie Gourley
• Mark Arends

Partners and Funders (current)

• ECRC/Award/Duration/Amount[DB1]